Maternal inflammation during pregnancy affects placental function and is associated with increased risk of neurodevelopmental disor
Introduction
Mechanistic links between maternal inflammation during pregnancy and the risk for developmental disorders in the offspring, including autism spectrum disorders (ASDs), cognitive delay, and schizophrenia, are being investigated intensively (Bonnin and Levitt, 2011; Stolp et al., 2011) . Intrauterine bacterial infection was shown to be an independent risk factor for early autistic features (Limperopoulos et al., 2008) and systemic maternal viral infection (e.g., influenza) has been reported as a risk factor for ASD and schizophrenia in the offspring (Patterson, 2002 (Patterson, , 2009 ). These associations are observed for both vertically (i.e., from mother to fetus) and nonvertically transmitted pathogens, suggesting that maternal inflammation resulting from exposure to these pathogens in and of itself is sufficient to alter fetal neurodevelopment. In support of this possibility, elevated concentrations of soluble proinflammatory and chemo-attractive cytokines in the maternal serum have been linked to neurodevelopmental disorders in the offspring (Bell and Hallenbeck, 2002) . Studies in rodents have demonstrated that systemic exposure to high doses of the immunostimulant polyriboinosinic-polyribocytidylic acid [poly(I:C)] induces a strong and sustained elevation in several proinflammatory cytokines, most notably interleukin-6 (IL-6), in the maternal serum. This dramatic induction of the maternal inflammatory pathway alters several neurodevelopmental processes and results in abnormal adult behavior in the offspring (Patterson, 2002 (Patterson, , 2009 Wang et al., 2009) . Intrauterine inflammation is observed in ϳ20% of all pregnancies and a staggering 85% of very premature births, the latter of which has also been associated with a number of neurodevelopmental disorders (Elovitz et al., 2011) . In addition, epidemiological observations of recent infectious diseases outbreaks (such as H1N1 influenza or Zika virus) suggest that pregnant women and their fetuses are high-risk groups for severe and long-lasting complications (Omer and Beigi, 2016) . This highlights the need to investigate the causal mechanisms underlying maternal inflammation and fetal neurodevelopment.
During pregnancy, a fraction of the maternal TRP is converted to 5-HT through the placental tryptophan hydroxylase (TPH1) enzymatic pathway, providing an exogenous source of 5-HT to the fetus. Prenatally, 5-HT modulates key neurodevelopmental processes, including axonal circuit formation (Gaspar et al., 2003; Bonnin et al., 2007 Bonnin et al., , 2011 van Kleef et al., 2012; Brummelte et al., 2016) . Another important placental TRP metabolic pathway is the conversion of TRP to kynurenine (KYN) by the indoleamine 2,3-dioxygenase (IDO1). This pathway protects the developing fetus from the maternal immune system at the early stages of pregnancy (Munn et al., 1998; Mellor and Munn, 2001) . Although the effects of IDO1 induction on the KYN pathway have been studied, the effects of maternal inflammation on placental 5-HT synthesis and delivery to the fetus have not. Although moderate induction of the IDO1 and TPH1 pathway during pregnancy is important from an immunosuppressive (countering maternal rejection) standpoint, altered 5-HT output to the fetus may affect neurodevelopment significantly.
Here, we used a well established prenatal immune challenge in mice to study the effects of maternal inflammation in midpregnancy on TRP metabolism in the placenta and the downstream consequences on fetal brain development. Moderate doses of poly(I:C) were used to induce a mild maternal immune challenge that was shown previously to induce significant long-term brain and behavioral deficits in the adult offspring (Meyer et al., 2005; Meyer and Feldon, 2012) . We observed that mild maternal inflammation during pregnancy leads to a transient increase of placental TRP concentration, followed by upregulation of Tph1 gene expression and increased TPH1 enzymatic activity in the placenta. These changes led to a sustained increase of placental 5-HT output to the fetus and ultimately increased 5-HT tissue concentration specifically within the fetal forebrain. Simultaneously, serotonergic axon outgrowth, a neurogenic process modulated by 5-HT signaling, was disrupted in this region. The pharmacological inhibition of TPH1 activity prevented the effects of maternal inflammation on fetal serotonergic development. These findings suggest that fetal brain serotonergic development is highly sensitive to maternal inflammation through disruptions of placental TRP metabolism to 5-HT.
Materials and Methods
Animals and maternal immune activation. Pregnant female CD-1 dams (Charles River Laboratories) were injected intraperitoneally at embryonic day 12 (E12; the copulatory plug date is considered E1) with saline (0.9% sterile solution; BD Biosciences, 297753) or 2 mg/kg poly(I:C) (Sigma-Aldrich, P9582) using 5 l/g per pregnant dam. For pharmacological inhibition of TPH activity experiments, dams were injected intraperitoneally at E12 with either saline or poly(I:C) (2 mg/kg) and para-cholorophenylalanine (pCPA; 300 mg/kg; Sigma-Aldrich, C6506). Dams were anesthetized and fetal forebrain, hindbrain, placenta, tail samples, and serum were harvested as described previously . SRY genotyping for the purpose of analyzing sex differences was performed on all fetuses. Fetal tissues from each litter were either fresh frozen or fixed and randomly assigned to subsequent analyses. All procedures involving animals were approved by the Institutional Animal Care and Use Committee.
qRT-PCR analysis. For mRNA expression analyses, three fresh-frozen fetal tissue samples from each dam were pooled and 40 mg of tissue was extracted for RNA using the Bio-Rad Aurum Total RNA Mini Kit according to the manufacturer's specifications. Extracted RNA was quantified and tested for purity spectrophotometrically and RNA quality was assessed using an Agilent Technologies 2100 bioanalyzer with high sensitivity RNA Screentape. Only samples with an RNA integrity number of 8.5 or higher and a 260/280 ratio of 1.8 -2.2 were used for subsequent qRT-PCR analysis. After quality assessment and quantification, 1 g of RNA was reverse transcribed to cDNA using the Invitrogen SuperScript III First-Strand Synthesis SuperMix for qRT-PCR kit according to the manufacturer's specifications. qRTPCRs were performed in triplicate using the Invitrogen Single Tube TaqMan Gene Expression Assays and TaqMan Gene Expression Master Mix and cycled and analyzed using the Invitrogen StepOnePlus Real-Time PCR System. Briefly, for each gene [Tph1 (Mm01202614_m1), Tph2 (Mm00557715_m1), Ido1 (Mm00492586_m1), Maoa (Mm00558004_m1), and reference gene TATA box binding protein (Tbp) (Mm00446973_m1)] and template combination 20 l reactions were set up in triplicate containing 10 l of TaqMan Gene Expression Master Mix, 1 l of TaqMan Gene Expression Assay, and 9 l of cDNA diluted in ultrapure water to a concentration of 10 ng template per well. Once all reactions were set up in 96-well plates, they were transferred to the StepOnePlus thermocycler and run using standard cycling conditions of a 2 min hold at 50°C, a 10 min hold at 95°C, and 50 cycles of 15 s at 95°C followed by 60 s at 60°C. Completed reactions were analyzed using the 2-⌬⌬C⌻ method (Livak and Schmittgen, 2001 ). The 2-⌬⌬C⌻ method for quantifying relative changes in gene expression involves comparing expression of a target gene with that of a reference gene that maintains stable expression throughout treatment groups and time points. Several reference genes were tested and TATA Box Binding Protein (Tbp) mRNA was found to be the most stable between treatment groups and time points in our samples. For the 2-⌬⌬C⌻ method to be valid, the amplification efficiencies of both the target and reference genes must be similar. To test this, efficiency curves for each TaqMan Assay were performed across a 100-fold template dilution range and compared for each primer-template combination to ensure similarity. After amplification, the relative expression of the control samples was compared with that of the treated samples and expressed in terms of fold change.
In vitro 5-hydroxytryptophan (5-HTP) synthesis assays. Harvested tissues (placenta, forebrain, and hindbrain) were thawed on ice and homogenized ultrasonically in, respectively, 400, 100, or 80 l of extraction buffer composed of 0.05 M Tris buffer, pH 7.5, containing 1 mM dithiothreitol and 1 mM EGTA. Homogenates were centrifuged at 21,000 ϫ g for 15 min at 4°C and then assayed for tryptophan hydroxylase activity. Briefly, 20 l of supernatant was added to tubes containing 80 l of reaction or control buffer to give a final concentration of: 0.05 M Tris buffer, pH 7.5, 1 mM EGTA, 50 g/ml catalase, 200 M L-tryptophan, 100 M ammonium iron (II) sulfate, and 100 M tetrahydrobiopterin (BH4; a cofactor required for TPH1 and TPH2 activity). Control buffers did not receive TRP or BH4. Tubes were incubated for 30 min at 37°C and reactions were terminated through protein denaturation by adding 100 l of 0.2 M percholoric acid with 100 M EDTA. Samples were stored on ice for 15 min to allow for complete protein denaturation and then centrifuged for 15 min at 21,000 ϫ g at 4°C. TRP metabolism was determined by measuring the 5-HTP concentration using HPLC with electrochemical detection (see below). Protein concentration of the supernatants was determined using a detergent-compatible protein assay (Bio-Rad) and enzymatic activity was quantified as picograms of 5-HTP/g of protein/30 min. Results are expressed as percentage of activity measured against salineinjected controls. Unless otherwise noted, all reagents were purchased from Sigma-Aldrich.
HPLC analysis. The HPLC analysis of perfusion samples and enzymatic assay supernatants was performed on an Eicom 700 system consisting of an ECD-700 electrochemical detector, an Eicom 700 Insight autosampler, and Envision integration software. An Eicompak SC-3ODS 3 m C18 reversed-phase column (3.0 ϫ 100 mm inner diameter) analytical column was used for separation. Samples were extracted in a 1:1 volume of 0.2 M perchloric acid with 100 M EDTA and a volume of 10 l was injected into the column. The mobile phase used for separation consisted of 0.1 M citric acid, 0.2 M sodium phosphate dibasic, 7% methanol (JT Baker, 9093-03), and 5 mg of EDTA in ultrapure water at a flow rate of 450 l/min. Unless otherwise noted, all reagents were purchased from Sigma-Aldrich. For measures of biogenic amine concentrations in fetal tissues, see Hervé et al. (1996) and Janusonis et al (2006) for detailed methodology.
Cytokine analysis. The maternal and placental inflammatory response to poly(I:C) or saline was quantified in every mouse by measuring the concentration of an array of cytokines and chemokines in serum or tissue homogenates at time of harvesting. Tissue concentrations were measured in the maternal serum, placenta, and fetal brains for the following cytokines/chemokines: CCL2-5, CXCL1, CXCL9, IL-1a/b, IL-2, IL-4, IL-6, IL-10, IL-17, IL-23, IFN␥, and TNF␣. For serum preparation, whole blood was collected and allowed to coagulate at 4°C for 30 min before centrifugation at 2000 ϫ g for 10 min at 4°C. Serum supernatant was collected and stored at Ϫ70°C. Placental and fetal brain tissues were homogenized immediately upon collection in 3 volumes (microliters per milligram) of ice-cold PBS supplemented with commercially available protease inhibitor mixture (Cell Signaling Technology, 5871S). Homogenates were clarified by centrifugation at 12,000 ϫ g for 10 min at 4°C, and then supernatants were collected and stored at Ϫ70°C. For assessment of solute concentrations, we used commercially available cytometric bead arrays (CBAs) (BD Biosciences) as described previously (Lund et al., 2004) . To assay, all samples were thawed on ice, diluted 1:3 in the supplied dilution buffer, and then run in triplicate. The concentration of each solute was calculated based on a standard curve of known concentrations and the intra-assay variability accounted for using internal control samples. The CBA sample data were collected using a BD Biosciences Accuri cytometer and analyzed using the commercially available FCAP Array Software (BD Biosciences). The mean sample concentration from serum is given as picograms per milliliter and that from tissue as picograms per milliliter of tissue homogenate.
Ex vivo placental perfusion 5-HT synthesis assay. For perfusion experiments, a separate cohort of pregnant dams was injected with either saline (n ϭ 4) or poly(I:C) (n ϭ 4) at E12. Briefly, a single placenta per dam was harvested at E14 and quickly transferred to a thermostatically controlled incubation chamber at 37°C. The uterine artery was cannulated with a 200-m-diameter catheter and perfused at 20 l/min with DMEM (Life Technologies, 11054-001) containing 200 M L-tryptophan and 100 M BH4. The umbilical artery was cannulated with a 105-m-diameter catheter and perfused at 5 l/min with DMEM. The eluate was collected from the umbilical vein for 90 min and analyzed for 5-HT concentration with HPLC. (For detailed methodology, see Goeden and Bonnin, 2013) .
Neurodevelopmental assays. Fetal brains were dissected in ice-cold PBS, immediately transferred to 4% paraformaldehyde (PFA), and incubated at 4°C for 24 h. The fetal brains were then incubated in 10%, 20%, and 30% sucrose (dissolved in PBS) for 24 h each at 4°C. After incubation, the brains were embedded in cryomolds on dry ice using Tissue Tek embedding medium (VWR, 25608-930) and stored at Ϫ80°C until sectioning. Embedded brains were removed from the Ϫ80°C freezer the night before sectioning and allowed to warm to Ϫ20°C. Fetal brains were sectioned coronally with a thickness of 20 m and sectioned tissue was stored at Ϫ80°C until immunohistochemical analysis. Sections were permeabilized with 0.1% Triton X-100 in 2% fetal bovine serum in PBS and incubated overnight at 4°C with primary antibodies: rabbit anti-5HT (final concentration 58 g/ml; Sigma-Aldrich, S5545). After extensive washing in PBS with 0.1% Triton X-100, slides were incubated at room temperature for 2 h with secondary antibody: Rhodamine Red-X-conjugated donkey anti-rabbit (1:800; Jackson ImmunoResearch Laboratories). Images were acquired with a Zeiss AxioCam MRm camera using Zeiss AxioVision version 4.8.2 software. 5-HT fluorescence intensity distribution was quantified using ImageJ. In every section, the fluorescence intensity was normalized to the background.
Statistical analyses. In all experiments, dams were treated as individual experimental groups (1 dam, n ϭ 1) and fetuses (n ϭ 3-5 of either sex per dam) as biological repeats. For every measure, the number of dams used in each group is indicated in the figures. For cytokine analyses, qRT-PCR, HPLC, and enzymatic activity assays, the statistical significance of differences between groups was assessed using two-way ANOVA (followed by Bonferroni correction for multiple comparisons, assuming that significant ( p Ͻ 0.05) main effects were observed), with time points and treatments used as variables. Unless otherwise noted, statistical differences presented are for treatment effects. For ex vivo placental perfusion experiments and PCPA treatment experiments performed at a single time point, differences between groups were compared using unpaired t tests with the Holm-Sidak correction for multiple comparisons. For comparisons of 5-HT immunofluorescence distribution along the rostrocaudal extent of the fetal brain in the saline (control) group versus the poly(I: C)-treated group at a single time point, the Mann-Whitney U test was used. No sex differences were observed in any of the analyses. All analyses were performed using GraphPad Prism version 6 software.
Results
Mild inflammation increases placental TRP metabolism and 5-HT delivery to the fetus Pregnant dams were injected at E12 with 2 mg/kg poly(I:C) or saline solution (control) and the maternal, placental, and fetal inflammatory response was quantified in every mouse at time of harvesting (i.e., E12 ϩ 24 or 48 h). Of all cytokines tested, only the IL-6 concentration was significantly different in the maternal serum of poly(I:C)-treated dams compared with saline-injected controls (overall effect of treatment: p ϭ 0.004, F ϭ 10.86, df ϭ 18) and only at the 24 h time point (increase of 92.3% over controls, p ϭ 0.0002). Importantly, despite the increased concentration of IL-6 in the maternal serum after poly(I:C) exposure, there was no change in fetal brain or placenta levels at 24 or 48 h (Fig. 1 A, B) . qRT-PCR analysis revealed significant effects of maternal inflammation on TRP metabolic gene expression in the placenta (Fig. 1C,D) . The most significant changes induced by poly(I:C) treatment over basal expression measured in controls obtained from saline-injected dams were observed for Ido1 (expression increased 4.2-fold and 1.9-fold at the 24 and 48 h time points, respectively; overall significant effect of treatment: p Ͻ 0.0001, F ϭ 707.0, df ϭ 14), followed by Tph1 gene expression (increased 2.5-fold at 24 h and decreased 2.7-fold at 48 h; overall significant effect of treatment: p Ͻ 0.0001, F ϭ 31.58, df ϭ 14); there was no effect of poly(I:C) exposure on Maoa gene expression at either time point (no significant overall effect of treatment: p ϭ 0.0855, F ϭ 3.424, df ϭ 14). There was no significant effect of treatment on any TRP metabolic gene expression (i.e., Maoa, Ido1, or Tph2) in the fetal brain at either time point (data not shown).
To determine whether altered gene expression ultimately affects the placental conversion of maternal TRP to 5-HT, we mea-sured TPH1/2 enzymatic activity directly in placentas and brains harvested from a subset of the same litters. There was a significant effect of exposure to poly(I:C) on TPH1 activity in the placenta (overall significant effect of treatment: p ϭ 0.0316, F ϭ 6.766, df ϭ 8); TPH1 activity was significantly increased 48 h after treatment ( p ϭ 0.009) only. In contrast, TPH2 enzymatic activity was not significantly altered by poly(I:C) exposure in the fetal hindbrain either 24 or 48 h after treatment (no significant overall effect of treatment: p ϭ 0.3728, F ϭ 0.8913, df ϭ 8; Fig. 2A ). To determine whether the increase in placental TPH1 enzymatic activity affects placental 5-HT synthesis and delivery to the fetus, we measured the real-time 5-HT output of ex vivo perfused placentas from saline-and poly(I:C)-injected dams. We observed a significantly increased (t (6) ϭ 2.7, p ϭ 2.0E-2) concentration of 5-HT released into the umbilical vein when comparing placentas from poly(I:C) exposed dams with placentas from control dams (Fig.  2B ). These results demonstrate that a mild maternal inflammation induces a cascade of genetic and enzymatic changes within the placenta that result in increased 5-HT output to the fetus after 48 h.
Fetal forebrain 5-HT increases rapidly after mild maternal immune activation
Consistent with previous findings that placental 5-HT synthesis affects fetal forebrain 5-HT concentration (Bonnin et al., 2011; Goeden and Bonnin, 2013), there was overall a significant effect of poly(I:C) treatment on fetal forebrain 5-HT tissue concentration ( p ϭ 0.0028, F ϭ 14.71, df ϭ 11; Fig. 3 A, C) ; although 5-HT tissue concentration was elevated at both time points after poly(I:C) exposure, the increase was significant only 48 h after treatment (comparison with saline controls: p ϭ 0.1342 at 24 h; p ϭ 0.0130 at 48 h). The treatment had no significant effect on hindbrain 5-HT tissue concentration at either time point ( p ϭ 0.8094, F ϭ 0.0610, df ϭ 11; Fig. 3 B, D) . Fetal brain tissue concentrations of 5-HIAA, the primary metabolite of 5-HT, remained unchanged at both time points ( p ϭ 0.1384, F ϭ 2.553, df ϭ 11). The concentration of 5-HTP in the fetal forebrain was below detection levels at these time points (data not shown). Poly(I:C) treatment also had a significant overall effect on KYN tissue concentration in the fetal forebrain ( p ϭ 0.0022, F ϭ 15.67, df ϭ 11; Fig. 3 A, C) and hindbrain ( p ϭ 0.0208, F ϭ 7.263, df ϭ 11; Fig. 3 B, D) . Importantly, there was an overall effect of poly(I:C) exposure on placental TRP concentration ( p ϭ 0.0058, F ϭ 11.67, df ϭ 11; Fig. 3E) , with a significant increase at 24 h (1.4-fold over saline-injected controls, p ϭ 0.0006 ), but not 48 h ( p Ͼ 0.9999). To test the possibility that increased substrate (TRP) availability in the placenta 24 h after poly(I:C) injection leads to increased metabolic conversion to 5-HT, we performed dose-response studies in placentas 24 h after poly(I:C) or saline injections. The in vitro enzymatic activity assays demonstrated that increasing input concentrations of TRP led to a linear increase of 5-HTP production in both the saline (r 2 ϭ 0.9996) and poly(I:C) (r 2 ϭ 0.9972) groups. Therefore, placental 5-HT synthesis is correlated linearly to TRP substrate availability (Fig. 3F ) . 
Decreased 5-HT axon outgrowth in the fetal forebrain
In addition to increased placental output, elevated forebrain 5-HT tissue concentration could have resulted from increased endogenous serotonergic axon outgrowth into the region. To test this possibility, we measured serotonergic (5-HT-immunoreactive, 5-HTϩ) axon density systematically throughout the rostrocaudal extent of the fetal forebrain 48 h after maternal exposure to saline, poly(I:C), or poly(I:C) and the TPH inhibitor pCPA (Fig. 4A) . When comparing sets of sections at matching rostrocaudal levels, densitometric analysis of fluorescence distribution showed a significant decrease of 5-HTϩ axon density in the rostral two-thirds of the forebrain in the poly(I:C)-treated, but not the poly(I:C) ϩ pCPA-treated group, compared with saline (Fig. 4B) . The overall 5-HTϩ axon density over the entire rostrocaudal axis was significantly decreased in the poly(I:C)-treated group compared with saline, but not after the coadministration of poly(I:C) with pCPA ( Fig. 4B ; Mann-Whitney test, U ϭ 60, p ϭ 0.0009). Furthermore, HPLC analyses showed that coadministration of pCPA prevents the accumulation of 5-HT in the fetal forebrain that is induced by poly(I:C) exposure alone versus the poly(I:C) ϩ pCPA group (t (6) ϭ 4.94, p ϭ 0.002; saline group versus poly(I:C) ϩ pCPA group: t (6) ϭ 1.81, p ϭ 0.119; Fig.  4C ). These results show that the elevation of 5-HT in the forebrain after mild inflammation is not due to increased serotonergic axon outgrowth into the region. Rather, the results suggest that elevated placental output of 5-HT after mild immune activation leads to increased extracellular 5-HT accumulation in the fetal forebrain that affect serotonergic axon rostral outgrowth negatively.
Discussion
Our results identify a novel molecular pathway by which maternal inflammation during pregnancy alters specific aspects of fetal brain development. We used a mild maternal immune challenge [2 mg/kg poly(I:C) administered i.p. at E12] with the following characteristics: (1) it does not lead to the accumulation of cytokines in the fetal brain, (2) it mimics clinically common mild inflammation with transient cytokine elevations in the maternal serum (Giovanoli et al., 2013; Meyer, 2014) , and (3) it induces significant long-term brain and behavioral deficits in the adult offspring (Meyer et al., 2005; Meyer and Feldon, 2012) . Importantly, whereas the mild immune challenge induced the expected transient IL-6 increase in the maternal serum, there was no evidence of cytokine accumulation in the fetal brain tissue (Fig. 1) . This suggests, not only that mild subclinical maternal inflammation does not alter overall placental permeability to cytokines, but also that it primarily involves indirect effects on the fetal brain (Bergström, 2003; Tincani et al., 2005; Seong et al., 2008; Romero et al., 2014 ) that may be mediated in part by cytokine interactions with placental toll-like receptors (Girard et al., 2010) .
Consistent with an indirect action of maternal inflammation on the fetal brain through alteration of placental function, our results show that low-dose poly(I:C) exposure affects placental TRP metabolism directly upstream of the fetus. The increase in Figure 2 . Maternal inflammation increases placental TPH1 enzymatic activity and ex vivo 5-HT output to the fetus. A, Twenty-four and 48 h after saline (control) or poly(I:C) (2 mg/kg) injections at E12, TRP to 5-HTP conversion, which reflects TPH enzymatic activity, was measured in placentas (TPH1) and fetal hindbrains (TPH2). Maternal inflammation induces a significant increase in TPH1 activity over saline (control) level (measured in placental extracts from saline injected dams) at 48 h only. TPH2 activity in the hindbrain is unchanged at both the 24 and 48 h time points. *p Ͻ 0.05, two-way ANOVA with Bonferroni correction. B, Ex vivo placental perfusions showing that significantly more 5-HT is synthesized and released from the placenta 48 h after maternal poly(I:C) exposure compared with saline (control) exposure. *p Ͻ 0.05, unpaired t test with Holm-Sidak correction. Error bars indicate SEM percentage change (A) or SD (B). n ϭ 3 (A) or n ϭ 1 (B) placentas per dam.
placental Ido1 gene expression in response to inflammation demonstrated here is consistent with previously published studies (Shayda et al., 2009; Wang et al., 2010) and, together with cytokine measures, confirms that the injection of low-dose poly(I:C) at E12 induces an inflammatory response in the mother that is attenuated locally in the placenta. This upregulation of the IDO1 pathway is critical for the localized suppression of the maternal immune response to protect the semiallogeneic fetus from rejection (Du et al., 2014) . It was hypothesized recently that such upregulation would lead to decreased TRP substrate availability for the competing TPH1 pathway, ultimately decreasing placental output of 5-HT to the developing fetal brain (Sato, 2013) . Contrary to this hypothesis, our results reveal a transient increase of TRP in the placenta 24 h after poly(I:C) exposure (Fig. 3F ) . Simultaneously, 5-HT tissue concentration is increased in the fetal forebrain (Fig. 3A) , but not the placenta (Fig. 3E) . Because the maternal blood compartment represents ϳ30% of the placental volume (Coan et al., 2008 (Coan et al., , 2010 , these data suggest that the maternal TRP, but not 5-HT, blood level is increased 24 h after poly(I:C) injection. Importantly, placental TPH1 enzymatic activity is normal at the 24 h time point (Fig. 2A) ; however, doseresponse studies (Fig. 3F ) show that increasing concentrations of TRP substrate (up to fourfold above the normal physiological concentrations of ϳ 60 M; Schröcksnadel et al., 2006) induce a linear increase of 5-HT synthesis. By 48 h after poly(I:C) injection, the placental TRP concentration returns to control level (Fig. 3E) , whereas placental TPH1 enzymatic activity is increased significantly compared with saline-injected controls ( Fig. 2A) . Therefore, two different mechanisms contribute successively to the elevation of fetal forebrain 5-HT measured 24 and 48 h after maternal poly(I:C) injection: (1) 24 h after induction of maternal inflammation, the transient elevation of maternal blood/placental TRP leads to increased output of placental 5-HT to the fetus and (2) at 48 h, the placental TRP concentration has returned back to normal levels (Fig. 3E ) but TPH1 enzymatic activity is increased ( Fig. 2A) , leading to increased placental 5-HT output to the fetus (Fig. 2B) . This chronological sequence of molecular changes results in a sustained elevation of fetal brain 5-HT lasting for at least 48 h after induction of maternal inflammation. The 5-HTP intermediate metabolic product produced by placental TPH1 activity (Fig. 3F ) might also get converted to 5-HT within the fetal forebrain; however, 5-HTP was not detected in the fetal forebrain at either time point, suggesting that the contribution of this pathway to the increase in 5-HT concentration is minimal. The results also suggest that transfer of maternal blood 5-HT to the fetus is unlikely to contribute to elevated fetal brain 5-HT levels. Indeed, poly(I:C) injections do not alter total maternal blood/placental 5-HT concentration significantly (Fig. 3E ) and, to our knowledge, there is no evidence of active transport of 5-HT across the placenta. Early studies (Robson and Senior, 1964) and more recent studies show that maternal blood 5-HT does not cross to the fetal compartment to a measurable extent. In fact, the absence of active maternalfetal 5-HT transport during this time period (E12-E14) may be consistent with the lack of 5-HT-specific transporter SERT expression in early pregnancy in the mouse placenta (Verhaagh et al., 2001) . Importantly, the increase of forebrain 5-HT is not associated with a decrease in 5-HIAA concentration, indicating that it does not result from decreased 5-HT degradation in the fetal brain. The direct in vivo measure of increased 5-HT output from the placenta to the fetal blood compartment in response to inflammatory challenge was not possible due to the very small volumes of blood collected at E13/14. However, the data indicate that the elevation of fetal forebrain 5-HT concentration measured after the maternal immune challenge results directly from increased placental 5-HT output. First, maternal inflammation upregulates TRP substrate availability and TPH1 enzymatic activity in the placenta, but not TPH2 activity in the fetal hindbrain ( Fig. 2A) . Second, the increase of 5-HT tissue concentration is significant in the fetal forebrain, but not hindbrain, where endogenous 5-HT neuronal cell bodies and proximal axons are located. Third, immunohistochemical analysis shows that maternal inflammation induces a significant decrease, not increase, of 5-HT axon outgrowth specifically into the rostral forebrain (Fig. 4B) . Fourth, coadministration of the selective TPH inhibitor pCPA prevents, not only the accumulation of 5-HT, but also the blunting of endogenous serotonergic axon outgrowth induced by maternal inflammation in the fetal forebrain. This effect took place between E12 and E14, a period of active serotonergic axon outgrowth into the rostral forebrain (Lidov and Molliver, 1982; Wallace and Lauder, 1983) . The simultaneous increase in total tissue 5-HT concentration and decrease of 5-HT axons density in the forebrain indicates that, at early stages of development (before E14), tissue concentrations of 5-HT measured by HPLC reflect mainly extracellular rather than immunohistochemically visible axonal 5-HT. A similar observation was made in the fetal forebrain of E14 Pet-1 knock-out embryos, in which most of the rostral forebrain serotonergic axon bundle is missing but which contain a normal tissue concentration of 5-HT (Bonnin et al., 2007) . Increased extracellular 5-HT of placental origin may in fact affect endogenous serotonergic axon outgrowth directly in the rostral forebrain. Indeed, earlier studies showed that extracellular 5-HT concentrations regulate 5-HT axon outgrowth through subsets of 5-HT autoreceptors expressed either on dorsal raphe 5-HT neuron cell bodies or axons (Daubert and Condron, 2010) . This suggests that the blunted rostral serotonergic axon outgrowth observed after maternal immune challenge may be a direct consequence of elevated concentrations of exogenous placental 5-HT reaching the forebrain.
Together, these findings indicate that a mild and acute maternal immune challenge disrupts placental conversion of TRP to 5-HT upstream of the fetal brain, which ultimately affects specific aspects of fetal neurodevelopment (Fig. 4 A, B) . Importantly, although the simultaneous increase of TRP metabolic flux through both the IDO1 and TPH1 pathways in the placenta in response to maternal inflammation provides an important immunesuppressive protection for the fetus, it also leads to increased fetal brain exposure to elevated concentrations of 5-HT. Such an increase in ligand concentration affects important developmental processes in the fetal brain that are normally modulated by 5-HT at early stages of pregnancy. A mild maternal inflammation triggered by low-dose poly(I:C) exposure, similar to the challenge used in the current study, was shown to have long-term effects on offspring brain function and behavior, including disruption of latent inhibition, spatial working memory impairment, and reduced spatial exploration . Although these studies included doses and routes of administration for poly(I:C) similar to those used in the present study, results indicated that offspring behavioral outcomes are dose dependent and potentially mouse strain dependent . Nevertheless, it appears that prenatal inflammation can lead to increased anxiety and depression-like behaviors in the offspring, behaviors that are influenced by serotonergic function (Butkevich et al., 2003; Enayati et al., 2012; Lin et al., 2012) . The possibility that the effect of maternal inflammation on early serotonergic development has long-term consequences on 5-HT-dependent behaviors is also supported by studies showing that low-dose poly(I:C) exposure during pregnancy decreases serotonergic tone in specific brain regions of the adult offspring, such as the nucleus accumbens and hippocampus (Winter et al., 2009) . However, to what extent the early specific disruptions of serotonergic circuit formation reported here contribute to these long-term alterations of offspring brain function requires additional characterization. Further studies on the effects of infectious agents on placentally derived modulators of neurodevelopment are warranted, particularly in view of recent infectious diseases outbreaks (such as H1N1 influenza or Zika virus) suggesting that pregnant women and their fetuses are high-risk groups for severe and long-lasting complications (Omer and Beigi, 2016) .
